General Information of the Drug (ID: M6APDG04202)
Name
Mydicar
Synonyms
Mydicar (TN)
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D01NXF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) is a therapeutic target for Mydicar. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Mydicar through regulating the expression of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2). [1], [2]
References
Ref 1 Protective mechanism of demethylase fat mass and obesity-associated protein in energy metabolism disorder of hypoxia-reoxygenation-induced cardiomyocytes. Exp Physiol. 2021 Dec;106(12):2423-2433. doi: 10.1113/EP089901. Epub 2021 Nov 21.
Ref 2 Clinical pipeline report, company report or official report of Purple Biotech.